Regulatory Defects and Genetic Modifiers of Hemoglobinopathies

Article written and reviewed by Dr Luca Moretti

Regulatory defects of globin genes and genetic modifiers of hemoglobinopathies encompass different mechanisms and do not constitute a single form of thalassemia. Some variants act in cis on promoters, enhancers, silencers or Locus Control Regions of the alpha- or beta-globin clusters; others act in trans, modifying erythroid programs such as the switch from fetal to adult hemoglobin. Clinical significance must be defined for the specific variant and for any associated hemoglobinopathy.

Genetic Classification and Mechanisms

Cis-regulatory variants may reduce or increase transcription of a globin gene and include promoter mutations, deletions or rearrangements of enhancers and LCRs, and abnormalities of chromatin contact sites. Depending on the region involved, these defects may produce a specific thalassemia, HPFH or an atypical hemoglobin profile.

• Globin promoters and enhancers: directly modify expression of the gene on the same chromosome.
• BCL11A: variants of the erythroid enhancer may reduce repression of gamma-globin genes and increase HbF.
• KLF1: variants with different effects may alter HbF, HbA2 and other erythroid traits.
• HBS1L-MYB: polymorphisms at this locus are associated with quantitative differences in HbF and other hematologic traits.

Alpha-globin gene triplication is not a regulatory defect: it is a copy-number variation and may worsen beta-thalassemia by increasing the relative excess of alpha chains.

Clinical Effect

Many isolated variants are asymptomatic and are recognized because of unexpected HbF, atypical HbA2 or during family investigation. In beta-thalassemia, sickle cell disease or other hemoglobinopathies, a modifier may attenuate or worsen specific aspects of the phenotype. A single clinical picture, obligatory microcytosis or a common prognosis therefore cannot be assigned to the entire group.

Diagnosis and Investigations

Further investigation is indicated when clinical data and hemoglobin fractions do not agree with the principal genotype. The complete blood count, HPLC or electrophoresis and iron status define the phenotype; genetic testing is then selected in a targeted manner. Sequencing, NGS panels, MLPA, arrays or breakpoint analysis are not interchangeable and are not required in every case. Family studies may be essential to establish inheritance and allelic phase.

Treatment and Prognosis

An isolated, asymptomatic regulatory variant or modifier requires no treatment. When it modifies a thalassemia or structural hemoglobinopathy, management follows the underlying disease and its actual clinical severity. Prognosis cannot be generalized: it depends on the specific variant, the associated genotype and access to appropriate care.

Genetic Counseling and Complications

Genetic counseling must avoid treating every modifier as a recessive thalassemia allele. Reproductive risk depends on the locus, its phase relative to globin variants and the inheritance pattern. Complications do not belong to the modifier in the abstract, but to the underlying hemoglobinopathy when its phenotype is worsened.

References
1. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge University Press. 2nd ed. 2009.
2. Bain BJ. Haemoglobinopathy Diagnosis. Wiley-Blackwell. 3rd ed. 2020.
3. Forget BG, Bunn HF. Classification of the disorders of hemoglobin. Cold Spring Harb Perspect Med. 2013;3(2):a011684.
4. Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med. 2013;3(1):a011643.
5. Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013;342(6155):253–257.
6. Lettre G, Sankaran VG, Bezerra MAC, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008;105(33):11869–11874.
7. Perkins A, Xu X, Higgs DR, Patrinos GP, et al. Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants. Blood. 2016;127(15):1856–1862.
8. Bain BJ, Daniel Y, Henthorn J, de la Salle B, Hogan A, Roy NBA, et al.; British Society for Haematology. Significant haemoglobinopathies: A guideline for screening and diagnosis. Br J Haematol. 2023;201(6):1047-1065.
9. Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013;3(5):a011700.
10. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373–383.